Turn Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 4 quarters of results from Mar 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|
| Efficiency | ||||
| Assets AverageAssets Avg. | 8.23M | 15.40M | 17.80M | |
| Invested CapitalInvested Cap. | 7.72M | 14.82M | 12.86M | |
| Leverage & Solvency | ||||
| Interest Coverage RatioInterest Cover | -2.00 | -2.28 | ||
| Debt Ratio | 0.25 | 0.47 | 0.72 | |
| Times Interest Earned | -2.00 | -2.28 | ||
| Valuation | ||||
| Price to EarningsP/E | -53.23 | -54.68 | -116.32 | |
| Price to BookP/B | 24.75 | 15.58 | 316.58 | |
| Enterprise Value | 110.94M | 84.10M | 207.16M | |
| EV to EBIT | -50.57 | -67.49 | -127.25 | |
| EV to EBITDA | -50.57 | -67.49 | -127.25 | |
| Market Capitalization | 116.01M | 95.32M | 217.45M | |
| Price to FCFP/FCF | -95.88 | -58.38 | -224.83 | |
| EV to FCF | -91.68 | -51.51 | -214.19 | |
| EV to CFO | -91.68 | -51.51 | -214.19 | |
| Return Ratios | ||||
| Return on Capital Employed [ROCE]ROCE | -263.13% | -65.41% | -77.24% | |
| Return on Assets [ROA]ROA | -73.17% | -46.70% | -43.26% |